Name: flow cytometry-based assay for the monitoring of nk cell functions
Uploaded: 2016-10-30T15:00:00
Description: Watch this Scientific Journal Video about Flow Cytometry-based Assay for the Monitoring of NK Cell Functions at JoVE.com

Authors were supported by the German Cancer Aid (Max Eder Nachwuchsgruppe, Deutsche Krebshilfe; EU), the LOEWE Center for Cell and Gene Therapy Frankfurt (EU, ST) funded by the Hessian Ministry of Higher Education, Research and the Arts, Germany (III L 4- 518/17.004) and by the "Alfred- und Angelika Gutermuth-Stiftung", Frankfurt, Germany (EU). BJ was funded by a Mildred Scheel postdoctoral scholarship from the Dr. Mildred Scheel Foundation for Cancer Research. ST was founded by a GO-IN postdoctoral fellowship (PCOFUND-GA-2011-291776). The authors thank Becton Dickinson (BD) for providing the FACSCanto II and Canto10c Flow Cytometry Analyzers used in this study.

Este estudo foi realizado de acordo com as recomendações do comitê de ética local da Universidade de Frankfurt. 1. Cultura de células K562 <ol><li> Cultura de células K562 em meios R10 (RPMI 1640 com meio de glutamina, 1% de penicilina / estreptomicina, 10% de soro fetal de vitela) a uma densidade de 0,5-1 x 10 6 culas por ml num balão de cultura de células a 37 ° C e 5% de CO 2. </li><li> Células colheita K562 24 h antes do início de uma nova experiência. <ol><li> Retirar o f...

<ol>
	<li>Watzl, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=How+to+trigger+a+killer:+modulation+of+natural+killer+cell+reactivity+on+many+levels.">How to trigger a killer: modulation of natural killer cell reactivity on many levels.</a> Adv Immunol. 124, 137-170 (2014).</li><li>Khaznadar, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Defective+NK+Cells+in+Acute+Myeloid+Leukemia+Patients+at+Diagnosis+Are+Associated+with+Blast+Transcriptional+Signatures+of+Immune+Evasion.">Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion.</a> J Immunol. 195 (6), 2580-2590 (2015).</li><li>Pical-Izard, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Reconstitution+of+natural+killer+cells+in+HLA-matched+HSCT+after+reduced-intensity+conditioning:+impact+on+clinical+outcome.">Reconstitution of natural killer cells in HLA-matched HSCT after reduced-intensity conditioning: impact on clinical outcome.</a> Biol Blood Marrow Transplant. 21 (3), 429-439 (2015).</li><li>Ahlenstiel, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Early+changes+in+natural+killer+cell+function+indicate+virologic+response+to+interferon+therapy+for+hepatitis+C.">Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.</a> Gastroenterology. 141 (4), 1231-1239 (2011).</li><li>Porrata, L. F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Early+lymphocyte+recovery+predicts+superior+survival+after+autologous+stem+cell+transplantation+in+non-Hodgkin+lymphoma:+a+prospective+study.">Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study.</a> Biol Blood Marrow Transplant. 14 (7), 807-816 (2008).</li><li>Silva, I. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Reversal+of+NK-cell+exhaustion+in+advanced+melanoma+by+Tim-3+blockade.">Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.</a> Cancer Immunol Res. 2 (5), 410-422 (2014).</li><li>Kiessling, R., Klein, E., Wigzell, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term="Natural"+killer+cells+in+the+mouse.+I.+Cytotoxic+cells+with+specificity+for+mouse+Moloney+leukemia+cells.+Specificity+and+distribution+according+to+genotype.">"Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype.</a> Eur J Immunol. 5 (2), 112-117 (1975).</li><li>Somanchi, S. S., Senyukov, V. V., Denman, C. J., Lee, D. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Expansion,+purification,+and+functional+assessment+of+human+peripheral+blood+NK+cells.">Expansion, purification, and functional assessment of human peripheral blood NK cells.</a> J Vis Exp. (48), (2011).</li><li>Mariani, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Chemokine+production+by+natural+killer+cells+from+nonagenarians.">Chemokine production by natural killer cells from nonagenarians.</a> Eur J Immunol. 32 (6), 1524-1529 (2002).</li><li>Reefman, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cytokine+secretion+is+distinct+from+secretion+of+cytotoxic+granules+in+NK+cells.">Cytokine secretion is distinct from secretion of cytotoxic granules in NK cells.</a> J Immunol. 184 (9), 4852-4862 (2010).</li><li>Jacobs, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=NK+Cell+Subgroups,+Phenotype,+and+Functions+After+Autologous+Stem+Cell+Transplantation.">NK Cell Subgroups, Phenotype, and Functions After Autologous Stem Cell Transplantation.</a> Front. Immunol. 6, 583 (2015).</li><li>Alter, G., Malenfant, J. M., Altfeld, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=CD107a+as+a+functional+marker+for+the+identification+of+natural+killer+cell+activity.">CD107a as a functional marker for the identification of natural killer cell activity.</a> J Immunol Methods. 294 (1-2), 15-22 (2004).</li><li>Theorell, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Sensitive+and+viable+quantification+of+inside-out+signals+for+LFA-1+activation+in+human+cytotoxic+lymphocytes+by+flow+cytometry.">Sensitive and viable quantification of inside-out signals for LFA-1 activation in human cytotoxic lymphocytes by flow cytometry.</a> J Immunol Methods. 366 (1-2), 106-118 (2011).</li><li>Brander, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Inhibition+of+human+NK+cell-mediated+cytotoxicity+by+exposure+to+ammonium+chloride.">Inhibition of human NK cell-mediated cytotoxicity by exposure to ammonium chloride.</a> J Immunol Methods. 252 (1-2), 1-14 (2001).</li><li>Beeton, C., Chandy, K. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Enrichment+of+NK+cells+from+human+blood+with+the+RosetteSep+kit+from+StemCell+technologies.">Enrichment of NK cells from human blood with the RosetteSep kit from StemCell technologies.</a> J Vis Exp. (8), e326 (2007).</li><li>Lamoreaux, L., Roederer, M., Koup, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intracellular+cytokine+optimization+and+standard+operating+procedure.">Intracellular cytokine optimization and standard operating procedure.</a> Nat. Protoc. 1 (3), 1507-1516 (2006).</li><li>Baginska, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Granzyme+B+degradation+by+autophagy+decreases+tumor+cell+susceptibility+to+natural+killer-mediated+lysis+under+hypoxia.">Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia.</a> Proc Natl Acad Sci U S A. 110 (43), 17450-17455 (2013).</li><li>He, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+sensitive+flow+cytometry-based+cytotoxic+T-lymphocyte+assay+through+detection+of+cleaved+caspase+3+in+target+cells.">A sensitive flow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in target cells.</a> J Immunol Methods. 304 (1-2), 43-59 (2005).</li><li>Sutton, V. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Serglycin+determines+secretory+granule+repertoire+and+regulates+NK+cell+and+CTL+cytotoxicity.">Serglycin determines secretory granule repertoire and regulates NK cell and CTL cytotoxicity.</a> FEBS J. 283 (5), 947-961 (2016).</li><li>Sch&#246;nberg, K., Hejazi, M., Uhrberg, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Protocol+for+the+clonal+analysis+of+NK+cell+effector+functions+by+multi-parameter+flow+cytometry.">Protocol for the clonal analysis of NK cell effector functions by multi-parameter flow cytometry.</a> Methods Mol Biol. 903, 381-392 (2012).</li><li>Bj&#246;rkstr&#246;m, N. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Expression+patterns+of+NKG2A,+KIR,+and+CD57+define+a+process+of+CD56dim+NK-cell+differentiation+uncoupled+from+NK-cell+education.">Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education.</a> Blood. 116 (19), 3853-3864 (2010).</li><li>Bryceson, Y. T., Ljunggren, H. G., Long, E. O. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Minimal+requirement+for+induction+of+natural+cytotoxicity+and+intersection+of+activation+signals+by+inhibitory+receptors.">Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors.</a> Blood. 114 (13), 2657-2666 (2009).</li><li>Cooper, M. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Human+natural+killer+cells:+a+unique+innate+immunoregulatory+role+for+the+CD56(bright)+subset.">Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.</a> Blood. 97 (10), 3146-3151 (2001).</li><li>Fauriat, C., Long, E. O., Ljunggren, H. G., Bryceson, Y. T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Regulation+of+human+NK-cell+cytokine+and+chemokine+production+by+target+cell+recognition.">Regulation of human NK-cell cytokine and chemokine production by target cell recognition.</a> Blood. 115 (11), 2167-2176 (2010).</li><li>Postow, M. A., Callahan, M. K., Wolchok, J. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Immune+Checkpoint+Blockade+in+Cancer+Therapy.">Immune Checkpoint Blockade in Cancer Therapy.</a> J Clin Oncol. 33 (17), 1974-1982 (2015).</li><li>Glienke, W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Advantages+and+applications+of+CAR-expressing+natural+killer+cells.">Advantages and applications of CAR-expressing natural killer cells.</a> Front Pharmacol. 6, 21 (2015).</li><li>Curran, K. J., Brentjens, R. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Chimeric+antigen+receptor+T+cells+for+cancer+immunotherapy.">Chimeric antigen receptor T cells for cancer immunotherapy.</a> J Clin Oncol. 33 (15), 1703-1706 (2015).</li><li>Zappasodi, R., de Braud, F., Di Nicola, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lymphoma+Immunotherapy:+Current+Status.">Lymphoma Immunotherapy: Current Status.</a> Front. Immunol. 6, 448 (2015).</li><li>Laprevotte, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Endogenous+IL-8+acts+as+a+CD16+co-activator+for+natural+killer-mediated+anti-CD20+B+cell+depletion+in+chronic+lymphocytic+leukemia.">Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia.</a> Leuk Res. 37 (4), 440-446 (2013).</li><li>Maloney, D. G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=IDEC-C2B8+(Rituximab)+anti-CD20+monoclonal+antibody+therapy+in+patients+with+relapsed+low-grade+non-Hodgkin's+lymphoma.">IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.</a> Blood. 90 (6), 2188-2195 (1997).</li><li>Salles, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Phase+1+study+results+of+the+type+II+glycoengineered+humanized+anti-CD20+monoclonal+antibody+obinutuzumab+(GA101)+in+B-cell+lymphoma+patients.">Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.</a> Blood. 119 (22), 5126-5132 (2012).</li><li>Terszowski, G., Klein, C., Stern, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=KIR/HLA+interactions+negatively+affect+rituximab-+but+not+GA101+(obinutuzumab)-induced+antibody-dependent+cellular+cytotoxicity.">KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.</a> J Immunol. 192 (12), 5618-5624 (2014).</li><li>Hsu, A. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+immunostimulatory+effect+of+lenalidomide+on+NK-cell+function+is+profoundly+inhibited+by+concurrent+dexamethasone+therapy.">The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.</a> Blood. 117 (5), 1605-1613 (2011).</li><li>Salih, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+BCR/ABL-inhibitors+imatinib,+nilotinib+and+dasatinib+differentially+affect+NK+cell+reactivity.">The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.</a> Int J Cancer. 127 (9), 2119-2128 (2010).</li><li>Benson, D. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+phase+1+trial+of+the+anti-KIR+antibody+IPH2101+in+patients+with+relapsed/refractory+multiple+myeloma.">A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.</a> Blood. 120 (22), 4324-4333 (2012).</li><li>Vey, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+phase+1+trial+of+the+anti-inhibitory+KIR+mAb+IPH2101+for+AML+in+complete+remission.">A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.</a> Blood. 120 (22), 4317-4323 (2012).</li><li>Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N., Zitvogel, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Natural+killer+cell-directed+therapies:+moving+from+unexpected+results+to+successful+strategies.">Natural killer cell-directed therapies: moving from unexpected results to successful strategies.</a> Nat Immunol. 9 (5), 486-494 (2008).</li></ol>

O método descrito é um método fácil, rápido e fiável para estudar as funções das células NK, a partir de amostras de sangue completo de dadores saudáveis ​​ou de pacientes. Este método oferece a grande vantagem de purificar as células NK directamente a partir de sangue total, evitando o demorado centrifugação em gradiente de densidade, que é obrigatória em muitos outros métodos de purificação 15. Além disso, requer um menor tamanho da amostra em relação ao &quot;clássico&quot; de is...

Como parte do sistema natural killer imune inata (NK) contribuir para a primeira linha de defesa contra as células infectadas com vírus ou transformadas de forma maligna. Um sistema de receptores inibidores e activadores lhes permite distinguir entre células transformadas e saudáveis ​​sem escorva antigénio antes em contraste com as células T. No momento do encontro célula alvo células NK liberar o conteúdo de seus grânulos citotóxicos (por exemplo, perforina, Granzimas) na sinapse imunológico para matar seu alvo. Além disso, as células NK produzem e segregam diferentes tipos de citocinas (por exemplo, interferão-y: IFN-γ; Factor de Necrose Tumoral-α: TNF-α) e quimiocinas (por exemplo, proteína inflamatória de macrófagos-1β: MIP-1b) sobre células alvo interacção citocina ou uma estimulação. Suficientes funções das células NK, tais como citotoxicidade, quimiocinas e produção de citocinas têm um impacto importante sobre o destino de diversas disfacilita. Pacientes com leucemia mostram taxas de recaída aumenta se eles apresentam um perfil de célula NK com defeito no momento do diagnóstico consiste em produção de IFN-γ reduzida e redução da expressão de ativação de receptores 2 células NK. Uma recuperação rápida do número de células NK e do funcionamento, incluindo a produção de citoquinas após interacção célula alvo está associada com uma recaída reduzida e uma melhor taxa de sobrevivência em doentes que receberam transplante de células estaminais alogénicas 3. Além disso, no início da terapêutica interferon em pacientes infectados pelo vírus da hepatite C a capacidade desgranulação das células NK periféricas é mais forte nos primeiros respondedores do que em não-respondedores 4. O número de células NK (&gt; 80 / l) no dia 15 após o transplante de células-tronco autólogas (autoSCT) em pacientes que sofrem de linfoma ou mieloma múltiplo são preditivos de uma melhor progressão livre e de sobrevida global 5. Em pacientes com melanoma, a expressão de a-célula T immunoglobulin- e mucina-domínio-contendg molécula-3 (TIM-3), uma proteína imuno-reguladora das células NK, correlaciona-se com a fase da doença e o prognóstico 6. Os cientistas têm monitorado as funções das células NK ao longo das últimas décadas. A análise inicial da citotoxicidade das células NK contra células tumorais sem escorva antes foi abordada utilizando um ensaio de libertação de 51Cr-7. Mais recentemente, os cientistas desenvolveram um método não-radioactivos para avaliar a citotoxicidade das células NK expandidos 8. Citocina e quimiocina produção tem sido frequentemente avaliado utilizando um ensaio de imunossorvente ligado técnicas a enzima (ELISA) 9,10. Durante as últimas décadas, estes métodos têm sido completada pelo fluxo de ensaios baseados em citometria. A utilização de inibidores de proteína de transporte (por exemplo, brefeldina A e monensina) e métodos de permeabilização celular em combinação com protocolos de coloração de superfície convencionais, permitiram aos cientistas estudar quimiocina e a produção de citocinas em diferentes linfa específicasubconjuntos ocyte (por exemplo, T, B ou células NK) 11. Além disso, ensaios baseados em citometria de fluxo diferentes têm sido desenvolvidos para monitorizar a citotoxicidade das células T e NK. Em 2004 Alter et ai. Descreveu a expressão de superfície da proteína associada ao lisossoma CD107a (LAMP1) em células NK mediante encontro de células alvo como um marcador para a desgranulação dos grânulos citotóxicos 12. Uma vez que uma ampla gama de diferentes fluorocromos e citómetros de fluxo multi-canal estão disponíveis nos nossos dias, tornou-se possível monitorizar simultaneamente diversas funções das células NK (citotoxicidade, produção de citoquinas e de quimioquinas) em diferentes subpopulações de células NK. Isto torna-se especialmente importante em situações em que o tamanho da amostra é limitado, por exemplo, em biopsias ou amostras de sangue de pacientes que sofrem de leucopenia. Para testar as funções das células NK globais, os ensaios baseados em citometria de fluxo diferente pode ser eficientemente combinada. Theorell et al. Células NK estimuladas de headoadores imunda com a linha de células tumorais K562 e analisados a desgranulação das células, o sinal de dentro para fora e de quimiocina produção NK através de citometria de fluxo 13. Recentemente subgrupos de células NK, fenótipos e funções em pacientes com tumor durante autoSCT foram analisados ​​por meio de fluxo ensaios baseados em citometria. Demonstrou-se que as células NK foram capazes de produzir desgranulam e citocinas / quimiocinas sobre o reconhecimento de células de tumor em tempos precoces depois autoSCT 11. Aqui é descrito um protocolo para avaliar as funções das células NK após interacção com células tumorais, incluindo a capacidade de desgranulação, produção de quimioquina e citoquina utilizando um fluxo de ensaio à base de citometria que faz com que seja possível controlar as funções das células NK em subconjuntos diferentes simultaneamente.

<table border="0" cellpadding="0" cellspacing="0" width="636">
	<colgroup>
		<col />
		<col />
		<col />
		<col />
	</colgroup>
	<tbody>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">RPMI 1640 + glutamine</td>
			<td style="width:135px;">Invitrogen</td>
			<td style="width:119px;">6187-044</td>
			<td style="width:167px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">penicilin/streptomycin</td>
			<td style="width:135px;">Invitrogen</td>
			<td style="width:119px;">15140-122</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">BD Falcon Round Bottom Tube</td>
			<td style="width:135px;">BD</td>
			<td style="width:119px;">352008</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:216px;">fetal calf serum</td>
			<td style="width:135px;">Invitrogen</td>
			<td style="width:119px;">10270-106</td>
			<td style="width:167px;">heat inactivated before use</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">T-flask</td>
			<td style="width:135px;">Greiner Bio-One</td>
			<td style="width:119px;">690195</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">K562 tumor cell line</td>
			<td style="width:135px;">DSMZ GmbH</td>
			<td style="width:119px;">ACC 10</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:216px;">ammonium-chloride-potassium (ACK) lysis buffer</td>
			<td style="width:135px;">made in house</td>
			<td style="width:119px;">/</td>
			<td style="width:167px;">components are listed in the text</td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:216px;">Distilled water: Ampuwa Sp&#252;ll&#246;sung 1000ml Plastipur</td>
			<td style="width:135px;">Fresenius Kabi</td>
			<td style="width:119px;">1088813</td>
			<td style="width:167px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">Megafuge 40R Centrifuge</td>
			<td>Heraeus</td>
			<td style="width:119px;">/</td>
			<td style="width:167px;"></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:216px;">EDTA blood collector tubes</td>
			<td style="width:135px;">Sarstedt</td>
			<td style="width:119px;">386453</td>
			<td style="width:167px;">S-Monovette 7,5 ml, K3 EDTA</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">UltraPure 0.5M EDTA, pH 8.0</td>
			<td>Life Technologies</td>
			<td style="width:119px;">15575-020</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">Hematopoietic media (XVIVO)</td>
			<td>Lonza Group Ltd</td>
			<td style="width:119px;">BE04-743Q</td>
			<td></td>
		</tr>
		<tr height="63">
			<td height="63" style="height:63px;width:216px;">human serum</td>
			<td style="width:135px;">DRK Blutspendedienst, Frankfurt/M&#160;</td>
			<td style="width:119px;">/</td>
			<td style="width:167px;">healthy donors with blood type AB; heat inactivated before use</td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:216px;">Neubauer-improved counting chamber, bright line</td>
			<td style="width:135px;">Marienfeld superior/ LO-Laboroptik Ltd.</td>
			<td style="width:119px;">0640030/ 1110000</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">trypan blue solution (0,4%)</td>
			<td>Invitrogen</td>
			<td style="width:119px;">15250-061</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:216px;">3% acetic acid with methylene blue</td>
			<td style="width:135px;">Stemcell Technologies&#160;</td>
			<td style="width:119px;">07060</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:216px;">Corning 96 Well Clear V-Bottom TC-treated Microplates</td>
			<td style="width:135px;">Corning&#160;</td>
			<td style="width:119px;">3894</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:216px;">Falcon 96 Well Round Bottom Not Treated Microplates</td>
			<td style="width:135px;">Corning&#160;</td>
			<td style="width:119px;">351177</td>
			<td></td>
		</tr>
		<tr height="25">
			<td height="25" style="height:25px;width:216px;">DPBS (Ca2+- and Mg2+-free)</td>
			<td style="width:135px;">Gibco Invitrogen</td>
			<td style="width:119px;">14190-169</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">BSA</td>
			<td style="width:135px;">Sigma Aldrich</td>
			<td style="width:119px;">A2153-100G</td>
			<td></td>
		</tr>
		<tr height="25">
			<td height="25" style="height:25px;width:216px;">NaN3</td>
			<td style="width:135px;">Sigma Aldrich</td>
			<td style="width:119px;">08591-1ML-F</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:216px;">phorbol 12-myristate 13-acetate (PMA)&#160;</td>
			<td style="width:135px;">Merck</td>
			<td style="width:119px;">524400-1MG</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:216px;">ionomycin&#160;</td>
			<td style="width:135px;">PromoKine</td>
			<td style="width:119px;">PK-CA577-1566-5</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">interleukin 15 (IL-15)</td>
			<td>PeproTech</td>
			<td>200-15</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">Proleukin S (IL-2)&#160;</td>
			<td style="width:135px;">Novartis Pharma</td>
			<td style="width:119px;">730523</td>
			<td></td>
		</tr>
		<tr height="126">
			<td height="126" style="height:126px;width:216px;">Golgi Stop, Protein Transport Inhibitor (containing Monensin)</td>
			<td style="width:135px;">BD Biosciences</td>
			<td style="width:119px;">554724</td>
			<td style="width:167px;">This product can be used in combination or instead of Golgi Plug. The best combination for the wished experimental setting has to be tested.</td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:216px;">Golgi Plug, Protein Transport Inhibitor (containing Brefeldin A)</td>
			<td style="width:135px;">BD Biosciences</td>
			<td style="width:119px;">555029</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">paraformaldehyde</td>
			<td style="width:135px;">AppliChem</td>
			<td style="width:119px;">UN2209</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">saponin</td>
			<td style="width:135px;">Sigma Aldrich</td>
			<td style="width:119px;">47036</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">flow cytometer: Canto10C</td>
			<td style="width:135px;">BD Biosciences</td>
			<td style="width:119px;">/</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">FlowJo</td>
			<td style="width:135px;">TreeStar Inc.</td>
			<td style="width:119px;">/</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">Graph Pad</td>
			<td style="width:135px;">Graph Pad Inc.</td>
			<td style="width:119px;">/</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">MACSxpress Separator</td>
			<td style="width:135px;">Miltenyi Biotec&#160;</td>
			<td style="width:119px;">130-098-308</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">MACSxpress NK isolation kit</td>
			<td style="width:135px;">Miltenyi Biotec&#160;</td>
			<td style="width:119px;">130-098-185</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:216px;">MACSxpress Erythrocyte Depletion Kit, human</td>
			<td style="width:135px;">Miltenyi Biotec&#160;</td>
			<td style="width:119px;">130-098-196</td>
			<td style="width:167px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">MACSmix Tube Rotator&#160;</td>
			<td style="width:135px;">Miltenyi Biotec&#160;</td>
			<td style="width:119px;">130-090-753</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">anti-human CD3 APC</td>
			<td style="width:135px;">Biolegend</td>
			<td>300412</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">anti-human CD3 V450</td>
			<td style="width:135px;">BD Biosciences</td>
			<td>560366</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">anti-human CD14 PerCP</td>
			<td style="width:135px;">Miltenyi Biotec&#160;</td>
			<td>130-094-969</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">anti-human CD14 V450</td>
			<td style="width:135px;">BD Biosciences</td>
			<td>560349</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">anti-human CD16 PE</td>
			<td style="width:135px;">Biolegend</td>
			<td>302008</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">anti-human CD16 PerCP</td>
			<td style="width:135px;">Biolegend</td>
			<td>302029</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">anti-human CD19 PE-Cy7</td>
			<td style="width:135px;">Biolegend</td>
			<td>302216</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">anti-human CD19 V450</td>
			<td style="width:135px;">BD Biosciences</td>
			<td>560353</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">anti-human CD45 BV510</td>
			<td style="width:135px;">BD Biosciences</td>
			<td>563204</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">anti-human CD56 FITC</td>
			<td style="width:135px;">Biolegend</td>
			<td>345811</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">anti-human CD107a PE</td>
			<td style="width:135px;">Biolegend</td>
			<td>328608</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">anti-human IFN-&#947; AF-647</td>
			<td style="width:135px;">BD Biosciences</td>
			<td>557729</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">anti-human MIP-1&#946; APC-H7</td>
			<td style="width:135px;">BD Biosciences</td>
			<td>561280</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:216px;">DAPI</td>
			<td style="width:135px;">Biolegend</td>
			<td>422801</td>
			<td></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Zombie Violet Fixable Viability Kit</td>
			<td>Biolegend</td>
			<td>423113</td>
			<td>fixable dead cell marker</td>
		</tr>
	</tbody>
</table>

flow cytometry-based assay for the monitoring of nk cell functions

Natural killer (NK) cells are an important part of the human tumor immune surveillance system. NK cells are able to distinguish between healthy and virus-infected or malignantly transformed cells due to a set of germline encoded inhibitory and activating receptors. Upon virus or tumor cell recognition a variety of different NK cell functions are initiated including cytotoxicity against the target cell as well as cytokine and chemokine production leading to the activation of other immune cells. It has been demonstrated that accurate NK cell functions are crucial for the treatment outcome of different virus infections and malignant diseases. Here a simple and reliable method is described to analyze different NK cell functions using a flow cytometry-based assay. NK cell functions can be evaluated not only for the whole NK cell population, but also for different NK cell subsets. This technique enables scientists to easily study NK cell functions in healthy donors or patients in order to reveal their impact on different malignancies and to further discover new therapeutic strategies.

<html> A estratégia de propagação para analisar a desgranulação, produção de citoquinas e de quimioquinas de toda a população de células NK e três subconjuntos de células NK diferentes estão ilustradas na Figura 1. Os resultados representativos de um dador saudável estão ilustrados na Figura 2. As células NK sem qualquer estímulo produzido nem IFN-γ nem MIP-1β e não manifest...

Watch this Scientific Journal Video about Flow Cytometry-based Assay for the Monitoring of NK Cell Functions at JoVE.com

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Um método simples e de confiança é descrito aqui para analisar um conjunto de funções das células NK, tais como desgranulação, produção de citocina e quimiocina dentro de diferentes subconjuntos de células NK.

Ensaio de citometria de fluxo baseada para a monitorização das funções das células NK

Natural killer (NK) cells are an important part of the human tumor immune surveillance system. NK cells are able to distinguish between healthy and ...

Research

JoVE Journal

Immunology and Infection

Monitoring Dendritic Cell Migration using 19F / 1H Magnetic Resonance Imaging

Monitoring Dendritic Cell Migration using 19F / 1H Magnetic Resonance Imaging

Monitoramento da Migração de Células dendríticas usando<sup&gt; 19</sup&gt; F /<sup&gt; 1</sup&gt; H Ressonância Magnética

Continuous  advancements in noninvasive imaging modalities such as magnetic resonance  imaging (MRI) have greatly improved our ability to study ...

Imunologia e Infecção

Cell-based Flow Cytometry Assay to Measure Cytotoxic Activity

Baseada em células de Citometria de Fluxo Ensaio medir citotóxicos Atividade

Cytolytic activity of CD8+ T cells is rarely evaluated. We describe here a new cell-based assay to measure the capacity of antigen-specific CD8+ T cells ...

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Analisando as funções das células de mastro em Vivo usando 'Mast Cell Knock-in' Ratos

Mast cells (MCs) are hematopoietic cells which reside in various tissues, and are especially abundant at sites exposed to the external environment, such ...

Isolation and Flow Cytometric Analysis of Immune Cells from the Ischemic Mouse Brain

Isolamento e análise de citometria de fluxo de células imunes do cérebro isquêmico Rato

Ischemic stroke initiates a robust inflammatory response that starts in the intravascular compartment and involves rapid activation of brain resident ...

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow

Classificação de células activadas por fluorescência Para a purificação de células dendríticas plasmocitï¿½des do rato de Medula Óssea

Fluorescence-activated cell sorting (FACS) is a technique to purify specific cell populations based on phenotypes detected by flow cytometry. This method ...

Assessing Retinal Microglial Phagocytic Function In Vivo Using a Flow Cytometry-based Assay

Assessing Retinal Microglial Phagocytic Function In Vivo Using a Flow Cytometry-based Assay

Avaliando Retinal microglia fagocítica Função<em&gt; In Vivo</em&gt; Usando um ensaio baseado em citometria de fluxo

Microglia are the tissue resident macrophages of the central nervous system (CNS) and they perform a variety of functions that support CNS homeostasis, ...

Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells

Dextran aumenta a eficiência de Lentivirus transdução das células NK primário murino e humano

The efficient transduction of specific genes into natural killer (NK) cells has been a major challenge. Successful transductions are critical to defining ...

A Flow Cytometry-Based Cytotoxicity Assay for the Assessment of Human NK Cell Activity

Um ensaio de citotoxicidade baseados em citometria de fluxo para a avaliação da atividade das células NK humana

Within the innate immune system, effector lymphocytes known as natural killer (NK) cells play an essential role in host defense against aberrant cells, ...

A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum

A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum

A citometria de fluxo simples com base em ensaio para determinar In Vitro anticorpo dependente do realce do vírus da Dengue, usando soro convalescente vírus Zika

Antibody dependent enhancement of infection has been shown to play a major role in Dengue viral pathogenesis. Traditional assays that measure the capacity ...

Multicolor Flow Cytometry-based Quantification of Mitochondria and Lysosomes in T Cells

Quantificação de baseados em citometria de fluxo multicolor de mitocôndrias e lisossomos em células T

T cells utilize different metabolic programs to match their functional needs during differentiation and proliferation. Mitochondria are crucial cellular ...